49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia

Spectrum of Acute Hyperglycemic Crises: DKA vs. HHS

Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) represent the two extreme poles of life-threatening acute metabolic decompensation in diabetes mellitus. While historically DKA was viewed as exclusive to type 1 diabetes and HHS to type 2 diabetes, significant clinical overlap occurs: up to 30% of patients present with features of both conditions.

Pathophysiologic Divergence

• Diabetic Ketoacidosis (DKA):
  • Absolute Insulin Deficiency: Triggered by omitted insulin, acute infection (pneumonia, UTI, sepsis), myocardial infarction, stroke, trauma, or pancreatitis. In the near-total absence of insulin, counterregulatory hormones (glucagon, cortisol, epinephrine, and growth hormone) surge unrestrained.
  • Uninhibited Lipolysis: Adipose tissue triglyceride breakdown is stimulated, flooding the portal circulation with free fatty acids (FFAs).
  • Hepatic Ketogenesis: In the liver, the enzyme carnitine palmitoyltransferase-1 (CPT-1) is disinhibited. FFAs enter hepatic mitochondria and undergo accelerated beta-oxidation to acetyl-CoA, which is channeled into the synthesis of ketone bodies: acetoacetate, beta-hydroxybutyrate (beta-OHB), and acetone.
  • Metabolic Acidosis: Beta-OHB and acetoacetate are strong organic acids (pKa ~4.0) that circulate fully dissociated, consuming serum bicarbonate and generating a high anion gap metabolic acidosis (Anion Gap = [Na+] - [Cl-] - [HCO3-] > 12 mEq/L).
  • Rapid Evolution: Develops acutely within <24 hours, with rapid onset of nausea, vomiting, abdominal pain (from visceral peritoneal stretching and prostaglandin release), and deep, rapid Kussmaul respirations to blow off carbon dioxide.
• Hyperosmolar Hyperglycemic State (HHS):
  • Relative Insulin Deficiency: Endogenous insulin secretion in type 2 diabetes is insufficient to stimulate peripheral glucose utilization in muscle and adipose tissue, but remains adequate to suppress adipose lipolysis and hepatic ketogenesis (only ~1/10th the concentration of insulin is required to block lipolysis as is needed for glucose disposal).
  • Massive Osmotic Diuresis: Severe, persistent hyperglycemia exceeds the renal proximal tubular resorptive capacity (typically >180-200 mg/dL). Unchecked glycosuria induces an unrelenting osmotic diuresis, leading to profound loss of water and electrolytes.
  • Extreme Hyperosmolality & Dehydration: Develops insidiously over days to weeks. By the time patients present, their fluid deficit is catastrophic (8 to 10 liters, or 100-200 mL/kg), serum glucose commonly exceeds 600 to 1,200 mg/dL, and effective serum osmolality surpasses 320 mOsm/kg, precipitating profound neurological depression (lethargy, stupor, focal seizures, coma).

                  DIAGNOSTIC CRITERIA: DKA VS. HHS

   Diagnostic Criterion          DKA (Mild / Mod / Severe)          HHS
   ═════════════════════════════════════════════════════════════════════════════════════════
   Plasma Glucose (mg/dL)        Typically 250 to 600 mg/dL         Markedly elevated: > 600 mg/dL
   Arterial pH                   < 7.30 (Severe: < 7.00)            Normal: > 7.30
   Serum Bicarbonate (mEq/L)     < 18 mEq/L (Severe: < 10)          Normal: > 18 mEq/L
   Serum / Urine Ketones         Strongly positive (Beta-OHB)       Absent or trace
   Serum Anion Gap               Elevated: > 10 to 12 mEq/L         Variable (usually normal <= 12)
   Effective Serum Osmolality    Variable (< 320 mOsm/kg)           Hyperosmolar: > 320 mOsm/kg
   Mental Status                 Alert to drowsy                    Stupor or coma
   Typical Fluid Deficit         Moderate: 4 to 6 Liters            Profound: 8 to 10 Liters
   Onset Velocity                Rapid: < 24 hours                  Insidious: Days to weeks
   ═════════════════════════════════════════════════════════════════════════════════════════
   Formula for Effective Serum Osmolality: 2 x [Measured Na+] + (Glucose / 18) [mOsm/kg]
   Formula for Serum Anion Gap: [Na+] - [Cl-] - [HCO3-] [mEq/L]

---

The Three-Pillar Clinical Management Protocol

Managing acute hyperglycemic emergencies requires concurrent, synchronized execution of three physiological pillars: intravenous fluid expansion, potassium stabilization, and insulin administration.

Pillar 1: Fluid Resuscitation

The immediate priority is restoring intravascular volume, stabilizing blood pressure, and establishing renal perfusion:

• Hour 1: Infuse 0.9% Normal Saline (0.9% NaCl) at a rate of 1,000 to 1,500 mL/hr (or 15 to 20 mL/kg/hr) in adults without heart failure.
• Subsequent Hours: Calculate the corrected serum sodium to adjust for the osmotic shift of intracellular water into the extracellular space: $\text{Corrected } [\text{Na}^+] = \text{Measured } [\text{Na}^+] + 1.6 \times \left(\frac{\text{Glucose} - 100}{100}\right)$ (Note: For glucose levels >400 mg/dL, a multiplier of 2.0 is often clinically applied).
  • If corrected sodium is normal (135-145 mEq/L) or elevated (>145 mEq/L): Switch fluids to half-normal saline (0.45% NaCl) at 250 to 500 mL/hr to replace free water deficits.
  • If corrected sodium is low (<135 mEq/L): Continue isotonic normal saline (0.9% NaCl) at 250 to 500 mL/hr.
• The Glycemic Threshold for Dextrose Addition:
  • In DKA: When blood glucose drops below 200 mg/dL, switch IV fluids to 5% Dextrose with 0.45% NaCl (D5 0.45% NaCl) while maintaining the insulin infusion at a reduced rate (0.02 to 0.05 units/kg/hr). Target blood glucose is maintained between 150 and 200 mg/dL until ketoacidosis completely clears.
  • In HHS: When blood glucose drops below 300 mg/dL, add 5% Dextrose (D5 0.45% NaCl), titrating insulin to maintain blood glucose between 200 and 300 mg/dL until hyperosmolality resolves and mental status normalizes.
  • Clinical Rationale: Halting or reducing insulin before ketoacidosis resolves causes immediate relapse. Adding dextrose prevents hypoglycemia while allowing continued insulin infusion to close the anion gap. Furthermore, it prevents precipitous drops in intravascular osmolality that trigger cerebral edema.

Pillar 2: Potassium Management & The Absolute Safety Rule

Total body potassium is invariably depleted in both DKA and HHS due to urinary loss from osmotic diuresis and gastrointestinal losses. However, measured initial serum potassium is often normal or elevated because acidosis and insulin deficiency cause potassium to shift out of intracellular stores into the serum.

[!CAUTION] THE ABSOLUTE POTASSIUM SAFETY RULE: NEVER GIVE INSULIN IF K+ < 3.3 Insulin drives potassium rapidly into cells via Na+/K+-ATPase activation, while rehydration dilutes serum potassium.

If serum potassium is < 3.3 mEq/L, HOLD THE INSULIN INFUSION COMPLETELY. Administer aggressive IV potassium replacement (20 to 40 mEq/hr) until serum K+ is >= 3.3 mEq/L. Administering insulin to a patient with severe hypokalemia can trigger lethal ventricular arrhythmias, respiratory muscle paralysis, and cardiac arrest.

• Potassium Triage Protocol:
  • Serum K+ < 3.3 mEq/L: HOLD INSULIN. Infuse potassium chloride at 20 to 40 mEq/hr until K+ rises >= 3.3 mEq/L. Then initiate insulin.
  • Serum K+ 3.3 to 5.2 mEq/L: Add 20 to 30 mEq potassium per liter of IV maintenance fluid (mix of 2/3 KCl and 1/3 KPO4 to replenish phosphate). Concurrently initiate insulin infusion. Target serum potassium: 4.0 to 5.0 mEq/L.
  • Serum K+ > 5.2 mEq/L: Do NOT add potassium to IV fluids. Initiate insulin infusion immediately. Check serum potassium every 2 hours; add potassium once levels fall below 5.2 mEq/L.

Pillar 3: Regular Insulin Administration & Titration

• Administration Regimen:
  • Continuous IV infusion of Regular Insulin: Either an initial IV bolus of 0.1 units/kg followed by a continuous infusion of 0.1 units/kg/hr, OR a continuous infusion of 0.14 units/kg/hr without a bolus.
  • Target rate of glucose decline: 50 to 75 mg/dL per hour. If glucose fails to fall by at least 50 mg/dL in the first hour, verify IV line patency and double the insulin infusion rate every hour until steady glycemic reduction is achieved.
• DKA Resolution Criteria: DKA is resolved ONLY when blood glucose is <200 mg/dL AND at least two of the following criteria are met:
  1. Serum bicarbonate >= 15 mEq/L (or >= 18 mEq/L per ADA 2023);
  2. Venous pH > 7.30;
  3. Normal serum anion gap (<= 12 mEq/L). (Note: Serum beta-hydroxybutyrate is the preferred marker to follow; urine acetoacetate nitroprusside dipsticks remain positive long after resolution and should not guide therapy).

[!IMPORTANT] THE 2-HOUR SUBCUTANEOUS BASAL INSULIN OVERLAP MANDATE Intravenous regular insulin has a biological half-life of only 4 to 5 minutes. If the IV insulin infusion is abruptly terminated, the patient is left with zero circulating insulin, precipitating rebound ketoacidosis within 1 to 2 hours.

Clinicians must administer subcutaneous basal insulin (e.g., glargine, detemir, degludec) at least 2 hours prior to stopping the IV insulin infusion. If the patient is eating, subcutaneous rapid-acting prandial insulin should also be administered with a meal at the time of discontinuation.

---

Euglycemic Diabetic Ketoacidosis (euDKA)

Euglycemic DKA is defined as the presence of ketoacidosis (arterial pH <7.30, serum bicarbonate <18 mEq/L, elevated anion gap >12 mEq/L, positive serum beta-hydroxybutyrate >=3.0 mmol/L) with normal or only mildly elevated blood glucose (<200 to 250 mg/dL).

Mechanism of SGLT2 Inhibitor-Induced euDKA

• Pharmacologic Class: Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors (canagliflozin, empagliflozin, dapagliflozin, ertugliflozin).
• Pathogenesis: By blocking SGLT2 in the proximal renal tubule, these agents induce continuous renal glycosuria (~70-100 g glucose/day excreted), artificially keeping blood glucose <200 mg/dL despite profound metabolic stress. Lower circulating glucose reduces pancreatic beta-cell insulin secretion, while concurrently stimulating pancreatic alpha cells to secrete glucagon. The resulting high glucagon-to-insulin ratio triggers massive lipolysis and hepatic ketogenesis.
• Precipitating Triggers: Acute surgical stress, severe intercurrent infection, low-carbohydrate or ketogenic diets, alcohol ingestion, dehydration, or inappropriate reduction of exogenous insulin doses.
• Preoperative Hold Guidelines:
  • Canagliflozin, Dapagliflozin, Empagliflozin: Withhold for at least 3 days (72 hours) prior to scheduled elective surgery.
  • Ertugliflozin: Withhold for at least 4 days (96 hours) prior to elective surgery.
  • Monitor serial venous blood gases, bicarbonate, and beta-hydroxybutyrate if patients on SGLT2 inhibitors become acutely ill, regardless of normal fingerstick glucose readings!

---

Acute Hypoglycemia: Triage, Rule of 15 & Toxicity Management

Hypoglycemia is the most common endocrine emergency, representing a major limiting factor in glycemic optimization for patients with diabetes.

Whipple's Triad & Diagnostic Stratification

True hypoglycemia is clinically established by Whipple's Triad:

1. Symptoms consistent with low blood glucose;
2. Documented low plasma glucose concentration (<70 mg/dL);
3. Prompt resolution of symptoms following carbohydrate administration.

                  ADA HYPOGLYCEMIA SEVERITY CLASSIFICATION

   Classification      Glycemic Level                 Clinical Manifestations & Actions
   ═════════════════════════════════════════════════════════════════════════════════════════════
   Level 1             < 70 mg/dL and >= 54 mg/dL     Autonomic warning signs (tremor, sweating);
   (Alert Value)                                      Patient self-treats with fast carbohydrates

   Level 2             < 54 mg/dL                     Clinically significant hypoglycemia;
   (Significant)                                      Neuroglycopenic symptoms begin

   Level 3             No specific glucose threshold  Severe cognitive impairment requiring external
   (Severe)            (typically < 40-50 mg/dL)      assistance for recovery (coma, seizure)
   ═════════════════════════════════════════════════════════════════════════════════════════════

Symptoms: Neurogenic vs. Neuroglycopenic

• Autonomic / Neurogenic Symptoms (mediated by sympathetic nervous system and epinephrine release): Diaphoresis, tremors, tachycardia, palpitations, anxiety, hunger, and pallor.
• Neuroglycopenic Symptoms (resulting from neuronal glucose deprivation): Confusion, irritability, dizziness, blurred vision, dysarthria, ataxia, behavioral changes, seizures, and loss of consciousness.
• Hypoglycemia Unawareness: Recurrent episodes of hypoglycemia blunt the autonomic sympathoadrenal response, eliminating early neurogenic warning signs. Patients transition directly into severe neuroglycopenia or coma without warning.

Conscious Management: The "Rule of 15"

For conscious patients able to swallow safely (Level 1 and Level 2 hypoglycemia):

1. Administer 15 to 20 grams of rapid-acting simple carbohydrate:
   • 4 ounces (1/2 cup) of fruit juice or regular (non-diet) soda;
   • 3 to 4 commercial glucose tablets;
   • 1 tube of glucose gel;
   • 5 to 6 hard candies. (Avoid complex carbohydrates or fat-rich foods like chocolate or peanut butter, as fats delay gastric emptying and slow glucose absorption).
2. Wait 15 minutes and recheck fingerstick blood glucose.
3. If blood glucose remains < 70 mg/dL, administer another 15 grams of fast-acting carbohydrate.
4. Once blood glucose normalizes (>=70 mg/dL), have the patient consume a complex carbohydrate and protein snack or meal (e.g., sandwich, crackers with cheese) to replenish hepatic glycogen stores.

Emergency Management of Severe Unconscious Hypoglycemia

For unconscious, seizing, or uncooperative patients unable to ingest oral carbohydrates:

• Intravenous Access Available: Administer 50% Dextrose in Water (D50W) 25 grams (50 mL) via slow IV push over 2 to 3 minutes. Follow with an IV infusion of 5% or 10% dextrose if needed to maintain glucose >100 mg/dL.
• No Intravenous Access:
  • Glucagon 1 mg intramuscular (IM) or subcutaneous (SC): Mobilizes hepatic glycogen stores; works within 10 to 15 minutes. Note: Glucagon is ineffective in patients with depleted glycogen stores (prolonged fasting, advanced cirrhosis, starvation, alcohol-induced hypoglycemia).
  • Intranasal Glucagon (Baqsimi) 3 mg single spray: Administered into one nostril; passively absorbed across the nasal mucosa without requiring active inhalation, effective even in nasal congestion.

Sulfonylurea-Induced Prolonged Hypoglycemia

• Pathophysiology: Sulfonylureas (glyburide, glimepiride, glipizide) stimulate continuous, glucose-independent insulin secretion by binding to the sulfonylurea receptor (SUR1) on pancreatic beta cells. Glyburide has active metabolites that accumulate in renal impairment, causing protracted hypoglycemia lasting 24 to 72 hours.
• The Dextrose Trap: Administering repeated IV dextrose boluses provides substrate that stimulates further endogenous insulin release from beta cells, precipitating "rebound" hypoglycemia.
• Mandatory Inpatient Management:
  1. Hospital Admission: Mandatory observation for at least 24 to 48 hours with continuous telemetry and serial hourly glucose checks.
  2. Octreotide Therapy: Octreotide (50 mcg SC every 8 to 12 hours). Octreotide is a synthetic somatostatin analogue that directly binds to somatostatin receptor subtype-2 (SSTR2) on beta cells, hyperpolarizing the cell membrane, closing voltage-gated calcium channels, and completely suppressing endogenous insulin secretion.